Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 3/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80649 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL3265329 | 0.85 | — | — | |
| 1,4-Butanediol SCHEMBL28624681 | 0.79 | GPR84 (0.55) | CAMK2AGPR84FFAR1FFAR4CYP3A4 | |
| SCHEMBL96092 | 0.79 | — | — | |
| Phosphoric Acid SCHEMBL16371652 | 0.79 | CAMK2A (0.37) | CAMK2AGPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL16372095 | 0.79 | CAMK2A (0.37) | CAMK2AGPR84FFAR1FFAR4 | |
| Oxybate SCHEMBL27865620 | 0.78 | CAMK2A (0.78) | CAMK2AGPR84FFAR1FFAR4KMT2A | |
| SCHEMBL7554526 | 0.77 | GPR84 (0.60) | CAMK2AGPR84FFAR1FFAR4CYP3A4 | |
| SCHEMBL95430 | 0.77 | GPR84 (0.60) | CAMK2AGPR84FFAR1FFAR4CYP3A4 | |
| SCHEMBL2839590 | 0.77 | GPR84 (0.60) | CAMK2AGPR84FFAR1FFAR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187434-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIX, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8497064-B2 | Nucleic acid labelling compounds | AFFYMETRIX, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | AFFYMETRIX, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8076072-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8026057-B2 | Nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIC, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7468243-B2 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | AFFYMETRIX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7423143-B2 | Nucleic acid labeling compounds | AFFYMETRIX. INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7291463-B2 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1385829-A4 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6864059-B2 | Biotin containing C-glycoside nucleic acid labeling compounds | AFFYMETRIX, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050003496-A1 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | AFFYMETRIX, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040210045-A1 | Nucleic acid labeling compounds | MCGALL GLENN (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040101892-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1385829-A2 | NUCLEIC ACID LABELING COMPOUNDS | Affymetrix, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030180757-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2003-09-25 | — | — | US | disclosed |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | AFFYMETRIX, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165372-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002072779-A2 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082289-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | CAMK2A 4689/4885GPR84 4031/4885FFAR1 3660/4885 |
| US-20080287667-A1 | Nucleic Acid Labeling Compounds | RNGTT, DUT, FBL | CAMK2A 4673/4885GPR84 3491/4885FFAR1 3340/4885 |
| US-20030180757-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | CAMK2A 4708/4885GPR84 4209/4885FFAR1 4194/4885 |
| US-20040101892-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | CAMK2A 4708/4885GPR84 4209/4885FFAR1 4194/4885 |
| US-20120053336-A1 | Nucleic Acid Labelling Compounds | RNGTT, DUT, FBL | CAMK2A 4740/4885GPR84 3852/4885FFAR1 3685/4885 |
| US-20020165372-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | CAMK2A 4708/4885GPR84 4209/4885FFAR1 4194/4885 |
| US-20050003496-A1 | Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis | DUT, PCNA, BCDIN3D | CAMK2A 4411/4885GPR84 4186/4885FFAR1 4473/4885 |
| US-20040210045-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | CAMK2A 4708/4885GPR84 4209/4885FFAR1 4194/4885 |
| US-20020182625-A1 | Nucleotide sequence labelling compoumd four use as tool in genetic engineering | RNGTT, POLM, RNMT | CAMK2A 4475/4885GPR84 4281/4885FFAR1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.